

Technické aspekty odběru a hodnocení biopsií prostaty u mužů s podezřením na včasný karcinom prostaty – první část

BARNABY CHAPPELL a JOHN McLOUGHLIN

Department of Urology, West Suffolk Hospital, Bury St Edmunds, Suffolk, UK

LITERATURA

- 1 Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ. Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980–97. *Urology* 2000; **56**: 817–22
- 2 Schroder FH, Wildhagen MF. Screening for prostate cancer. Evidence and perspectives. *BJU Int* 2001; **88**: 811–7
- 3 Carroll PR. Serum prostate-specific antigen for prostate cancer early detection: total, free, age-stratified, or complexed? *Urology* 2001; **57**: 591–3
- 4 Lee CT, Scardino PT. Percent free prostate-specific antigen for first-time prostate biopsy. *Urology* 2001; **57**: 594–8
- 5 Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. *J Urol* 1997; **157**: 2191–6
- 6 Anonymous. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for the Diagnosis of Prostate Cancer. *Eur Urol* 1997; **32**: 133–9
- 7 Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. *Cancer* 1997; **80**: 1852–6
- 8 Singh H, Canto EI, Shariat SF *et al*. Predictors of prostate cancer after initial negative systematic 12 core biopsy. *J Urol* 2004; **171**: 1850–4
- 9 Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0 ng/ mL and benign prostate examination. Enhancement of specificity with free PSA measurements. *JAMA* 1997; **277**: 1452–5
- 10 Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. *J Urol* 1998; **160**: 1734–8
- 11 Krumholtz JS, Carvalhal GF, Ramos CG *et al*. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. *Urology* 2002; **60**: 469–73
- 12 Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/ mL. *BJU Int* 2004; **93**: 499–502
- 13 Reissigl A, Pointner J, Horninger W *et al*. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. *Urology* 1995; **46**: 662–5
- 14 Wymenga LF, Duisterwinkel FJ, Groenier K, Mensink HJ. Ultrasoundguided seminal vesicle biopsies in prostate cancer. *Prostate Cancer Prostatic Dis* 2000; **3**: 100–6
- 15 Hayek OR, Noble CB, de la Taille A, Bagiella E, Benson MC. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free: total ratio) in men with prior negative prostatic biopsies. *Curr Opin Urol* 1999; **9**: 371–5
- 16 Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD). Role in patient evaluation and management. *Urol Clin North Am* 1993; **20**: 653–63
- 17 Littrup PJ, Kane RA, Mettlin CJ *et al*. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. *Cancer* 1994; **74**: 3146–58
- 18 Remzi M, Djavan B, Wammack R *et al*. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? *Urology* 2003; **61**: 161–6
- 19 Winkler MH, Kulinskaya E, Gillatt DA. Prediction of prostate cancer in extendedfield biopsies of the prostate. *BJU Int* 2004; **93**: 516–21
- 20 Djavan B, Remzi M, Zlotta AR *et al*. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition

- zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. *Urology* 2002; **60** (4 Suppl.1): 4-9
- 21 **Scaletsky RFM, Koff WJ.** PSA density of the transition zone and early detection of prostate cancer. *Prostate Cancer Prostatic Dis* 2002; **5** (Suppl 1): S29
- 22 **Roehl KA, Antenor JA, Catalona WJ.** Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng./ml. range. *J Urol* 2002; **168**: 922-5
- 23 **Parsons JK, Brawer MK, Cheli CD, Partin AW, Djavan R.** Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. *BJU Int* 2004; **94**: 47-50
- 24 **Carter HB, Pearson JD.** Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. *Urol Clin North Am* 1997; **24**: 333-8
- 25 **Richie JP, Catalona WJ, Ahmann FR et al.** Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. *Urology* 1993; **42**: 365-74
- 26 **Schroder FH, Denis LJ, Roobol M et al.** The story of the European Randomized Study of Screening for Prostate Cancer. *BJU Int* 2003; **92** (Suppl. 2): 1-13
- 27 **Flanigan RC, Catalona WJ, Richie JP et al.** Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. *J Urol* 1994; **152**: 1506-9
- 28 **Hodge KK, McNeal JE, Terris MK, Stamey TA.** Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *J Urol* 1989; **142**: 71-4
- 29 **Epstein JI, Walsh PC, Sauvageot J, Carter HB.** Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. *J Urol* 1997; **158**: 1886-90
- 30 **Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C.** The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. *Urology* 1997; **50**: 562-6
- 31 **Cookson MS.** Technical refinements of transrectal ultrasound-guided needle biopsy and re-biopsy of the prostate. *AUA Update Series* 2001; **20**: 82-7
- 32 **Bill-Axelsson A, Holmberg L, Norlen B, Busch C, Norberg M.** No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination. *J Urol* 2003; **170**: 1180-3
- 33 **Singh H, Canto EI, Shariat SF et al.** Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. *J Urol* 2004; **171**: 204-9
- 34 **Bott SR, Young MP, Kellett MJ, Parkinson MC.** Anterior prostate cancer: is it more difficult to diagnose? *BJU Int* 2002; **89**: 886-9
- 35 **Gore JL, Shariat SF, Miles BJ et al.** Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol* 2001; **165**: 1554-9
- 36 **Chang JJ, Shinohara K, Bhargava V, Presti JC Jr.** Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. *J Urol* 1998; **160**: 2111-4
- 37 **O'Dowd GJ, Miller MC, Orozco R, Veltri RW.** Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. *Urology* 2000; **55**: 553-9
- 38 **Makhlouf AA, Krupski TL, Kunkle D, Theodorescu D.** The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. *BJU Int* 2004; **93**: 271-4
- 39 **Egevad L, Norlen BJ, Norberg M.** The value of multiple core biopsies for predicting the Gleason score of prostate cancer. *BJU Int* 2001; **88**: 716-21
- 40 **Epstein JI, Walsh PC, Carter HB.** Importance of posterolateral needle biopsies in the detection of prostate cancer. *Urology* 2001; **57**: 1112-6
- 41 **Mariappan P, Chong WL, Sundram M, Mohamed SR.** Increasing prostate biopsy cores based on Volume vs the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. *BJU Int* 2004; **94**: 307-10
- 42 **Presti JC Jr, Chang JJ, Bhargava V, Shinohara K.** The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies. results of a prospective clinical trial. *J Urol* 2000; **163**: 163-6
- 43 **Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HH Jr.** The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. *J Urol* 2001; **165**: 757-60
- 44 **Descazeaud A, Allory Y et al.** Does a 21 prostate needle biopsies protocol improve the prediction of pT3 status positive surgical margins and tumour localization on radical

- prostatectomy specimens ?
AUA Meeting 2004. Abstract
864, 2004
- 45 **Eskew LA, Bare RL, McCullough DL.** Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. *J Urol* 1997; **157**: 199–202
- 46 **Ng LG, Yip S, Tan PH, Yuen J, Lau W, Cheng C.** Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. *Asian J Surg* 2002; **25**: 238–43
- 47 **Fink KG, Hutarew G, Esterbauer B et al.** Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsy. *Urology* 2003; **61**: 748–53
- 48 **Bauer JJ, Zeng J, Weir J et al.** Threedimensional computer-simulated prostate models. lateral prostate biopsies increase the detection rate of prostate cancer. *Urology* 1999; **53**: 961–7
- 49 **Chen ME, Troncso P, Johnston DA, Tang K, Babaian RJ.** Optimization of prostate biopsy strategy using computer based analysis. *J Urol* 1997; **158**: 2168–75
- 50 **Lui PD, Terris MK, McNeal JE, Stamey TA.** Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. *J Urol* 1995; **153**: 1000–3
- 51 **Bazinet M, Karakiewicz PI, Aprikian AG et al.** Value of systematic transition zone biopsies in the early detection of prostate cancer. *J Urol* 1996; **155**: 605–6
- 52 **Djavan B, Remzi M, Marberger M.** When to biopsy and when to stop biopsying. *Urol Clin North Am* 2003; **30**: 253–62
- 53 **Terris MK, Pham TQ, Issa MM, Kabalin JN.** Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. *J Urol* 1997; **157**: 204–6
- 54 **Djavan B.** Editorial comment. *Urology* 2000; **55**: 559
- 55 **Eskew LA, Woodruff RD, Bare RL, McCullough DL.** Prostate cancer diagnosed by the 5 region biopsy method is significant disease. *J Urol* 1998; **160**: 794–6
- 56 **Levine MA, Ittman M, Melamed J, Lepor H.** Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. *J Urol* 1998; **159**: 471–5
- 57 **Philip J, Ragavan N, Desouza J, Foster CS, Javle P.** Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. *BJU Int* 2004; **93**: 1218–20
- 58 **Iczkowski KA, Casella G, Seppala RJ et al.** Needle core length in sextant biopsy influences prostate cancer detection rate. *Urology* 2002; **59**: 698–703
- 59 **Egevad L, Frimmel H, Mattson S, Bengtsson E, Busch C.** Biopsy protocol stability in a three-dimensional model of prostate cancer: changes in cancer yield after adjustment of biopsy positions. *Urology* 1999; **54**: 862–8
- 60 **Feneley MR, Landis P, Simon I et al.** Today men with prostate cancer have larger prostates. *Urology* 2000; **56**: 839–42
- 61 **Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schroder FH.** Repeat screening for prostate cancer after 1-year followup in 984 biopsied men. clinical and pathological features of detected cancer. *J Urol* 1998; **160**: 2121–5
- 62 **Chen ME, Troncso P, Johnston D, Tang K, Babaian RJ.** Prostate cancer detection: relationship to prostate size. *Urology* 1999; **53**: 764–8
- 63 **Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr.** The influence of prostate size on cancer detection. *Urology* 1995; **46**: 831–6
- 64 **Seymour H, Perry MJ, Lee-Elliott C, Dundas D, Patel U.** Pain after transrectal ultrasonography-guided prostate biopsy. The advantages of periprostatic local anaesthesia. *BJU Int* 2001; **88**: 540–4
- 65 **Walker AE, Schelvan C, Rockall AG, Rickards D, Kellett MJ.** Does pericapsular lignocaine reduce pain during transrectal ultrasonographyguided biopsy of the prostate? *BJU Int* 2002; **90**: 883–6
- 66 **Irani J, Fournier F, Bon D, Gremmo E, Dore B, Aubert J.** Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. *Br J Urol* 1997; **79**: 608–10
- 67 **Wu CL, Carter HB, Naqibuddin M, Fleisher LA.** Effect of local anesthetics on patient recovery after transrectal biopsy. *Urology* 2001; **57**: 925–9
- 68 **Rabets JC, Jones JS, Patel AR, Zippe CD.** Bupivacaine provides rapid, effective periprostatic anaesthesia for transrectal prostate biopsy. *BJU Int* 2004; **93**: 1216–7
- 69 **Costello TG, Costello AJ.** Anaesthesia for laser prostatectomy. *Anaesth Intensive Care* 1994; **22**: 454–7
- 70 **Soloway MS, Obek C.** Periprostatic local anesthesia before ultrasound guided prostate biopsy. *J Urol* 2000; **163**: 172–3
- 71 **Schostak M, Christoph F, Muller M et al.** Optimizing local anesthesia during 10-core biopsy of the prostate. *Urology* 2002; **60**: 253–7
- 72 **Issa MM, Bux S, Chun T et al.** A randomized prospective trial of intrarectal lidocaine for pain control during transrectal

- prostate biopsy: the Emory University experience. *J Urol* 2000; **164**: 397-9
- 73 **Desgrandchamps F, Meria P, Irani J, Desgrippes A, Teillac P, Le Duc A.** The rectal administration of lidocaine gel and tolerance of transrectal ultrasonography-guided biopsy of the prostate: a prospective randomized placebo-controlled study. *BJU Int* 1999; **83**: 1007-9
- 74 **Lynn NN, Collins GN, Brown SC, O'Reilly PH.** Periprostatic nerve block gives better analgesia for prostatic biopsy. *BJU Int* 2002; **90**: 424-6
- 75 **Haq A, Patel HR, Habib MR, Donaldson PJ, Parry JR.** Diclofenac suppository analgesia for transrectal ultrasound-guided biopsies of the prostate: a double-blind, randomized controlled trial. *J Urol* 2004; **171**: 1489-91
- 76 **Moinzadeh A, Mourtzinou A, Triaca V, Hamawy KJ.** A randomized double-blind prospective study evaluating patient tolerance of transrectal ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib. *Urology* 2003; **62**: 1054-7
- 77 **Berger AP, Gozzi C, Steiner H et al.** Complication rate of transrectal ultrasound-guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. *J Urol* 2004; **171**: 1478-80
- 78 **Stewart CS, Leibovich BC, Weaver AL, Lieber MM.** Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. *J Urol* 2001; **166**: 86-91
- 79 **Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schröder FH.** Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. *Urology* 2002; **60**: 826-30
- 80 **Bozlu M, Ulusoy E, Doruk E et al.** Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity? *Urology* 2003; **62**: 1050-3
- 81 **Maan Z, Cutting CW, Patel U et al.** Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. *BJU Int* 2003; **91**: 798-800
- 82 **Enlund AL, Varenhorst E.** Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. *Br J Urol* 1997; **79**: 777-80
- 83 **Carey JM, Korman HJ.** Transrectal ultrasound-guided biopsy of the prostate. Do enemas decrease clinically significant complications? *J Urol* 2001; **166**: 82-5

Korespondence:

John McLoughlin,
Department of Urology,
West Suffolk Hospital,
Bury St Edmunds,
Suffolk IP33 2QZ, UK.
e-mail:
John.McLoughlin@wsh.nhs.uk

Zkratky:

(f, t, f/t) PSA, (free, total, free/total) PSA; TRUS-B, TRUS-guided biopsy; PPV, positive predictive value; RP, radical prostatectomy; PSAD, PSA density; PSATZD, PSAD of the transition zone; PZ, peripheral zone.